Amphinex

Last updated October 16, 2025

Amphinex is a photosensitising agent used in photodynamic therapy for treating superficial cancers.

It has had promising preliminary results in early trials on patients with advanced head and neck cancer ^[1]^[2]^[3]

References

↑ "Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells. | PCI Biotech". Archived from the original on 2011-07-24. Retrieved 2010-04-06. Successful completion of the third dose group in the Amphinex study. March 2010
↑ http://www.medicalnewstoday.com/articles/176431.php PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial. Jan 2010
↑ "Inoperable cancers killed by new laser surgery" The Times. UK. 3-April-2010 p15

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells. | PCI Biotech". Archived from the original on 2011-07-24. Retrieved 2010-04-06. Successful completion of the third dose group in the Amphinex study. March 2010

[2] ttp://www.medicalnewstoday.com/articles/176431.php PCI Biotech Reports Successful Completion Of Second Dose Group In Pivotal Amphinex(R) Trial. Jan 2010

[3] "Inoperable cancers killed by new laser surgery" The Times. UK. 3-April-2010 p15

[1]

[2]

[3]